Cannabis, cannabinoids and schizophrenia: Integration of the evidence

Australian and New Zealand Journal of Psychiatry

Volumn 42, Issue 5, 2008, Pages 357-368

  Cohen, Martin ^a   Solowij, Nadia ^b   Carr, Vaughan ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Cannabinoid; Cannabis; Comorbidity; Dual diagnosis; Psychosis; Schizophrenia

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; DOPAMINE TRANSPORTER; ENDOCANNABINOID; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMYGDALOID NUCLEUS; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN PERFUSION; CANNABIS ADDICTION; CLINICAL EVALUATION; COGNITIVE DEFECT; COMORBIDITY; DOPAMINE RELEASE; DYSPHORIA; GENETIC RISK; HIPPOCAMPUS POTENTIAL; HUMAN; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PHYSIOLOGICAL STRESS; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SHORT TERM MEMORY; STRUCTURE ANALYSIS;

ANIMALS; BRAIN; CANNABINOIDS; CANNABIS; COGNITION DISORDERS; ENDOCANNABINOIDS; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 45849151724     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670801961156     Document Type: Article

References (128)

1. Hall, W. and Solowij, N. (1998) Adverse effects of cannabis. Lancet, 352, pp. 1611-1616.
2. Perkonigg, A., Lieb, R., Hofler, M., Schuster, P., Sonntag, H. and Wittchen, H-U. (1999) Patterns of cannabis use abuse and dependence over time: Incidence progression and stability in a sample of 1228 adolescents. Addiction, 94, pp. 1663-1678.
3. Degenhardt, L. and Hall, W. (2001) The relationship between tobacco use, substance-use disorders and mental health: Results from the National Survey of Mental Health and Well-being. Nicotine Tob Res, 3, pp. 225-234.
4. Mathew, RJ, Wilson, WH, Turkington, TG and Coleman, RE. (1999) Cerebellar activity and disturbed time sense after THC. Brain Res, 797, pp. 183-189.
5. Bolla, KI, Eldreth, D., Matochik, J. and Cadet, JL. (2005) Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage, 26, pp. 480-492.
6. O'Leary, DS, Block, RI and Flaum, M. (2000) Acute marijuana effects on rCBF and cognition: A PET study. Neuroreport, 11, pp. 3835-3841.
7. Chang, L., Yakupov, R., Cloak, C. and Ernst, T. (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain, 129, pp. 1096-1112.
8. Quickfall, J. and Crockford, D. (2006) Brain neuroimaging in cannabis use: A review. J Neuropsychiatry Clin Neurosci, 18, pp. 318-332.
9. Wilson, WH, Mathew, RJ, Turkington, T., Hawk, TC, Coleman, RE and Provenzale, J. (2000) Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study. J Addict Dis, 19, pp. 1-22.
10. Aasly, J., Storsaeter, O., Nilsen, G., Smevik, O. and Rinck, P. (1993) Minor structural brain changes in young drug abusers: A magnetic resonance study. Acta Neurol Scand, 87, pp. 210-214.
11. Matochik, J., Eldreth, D., Cadet, J. and Bolla, K. (2005) Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend, 77, pp. 23-30.
12. Yucel, M., Solowij, N. and Respondek, C. Regional brain abnormalities associated with heavy long-term cannabis use. Arch Gen Psychiatry
13. Toga, AW and Thompson, PM. (2002) New approaches in brain morphometry. Am J Geriatr Psychiatry, 10, pp. 13-23.
14. Hambrecht, M. and Hafner, H. (2000) Cannabis vulnerability and the onset of schizophrenia: An epidemiologic perspective. Aust N Z J Psychiatry, 34, pp. 468-475.
15. Andreasson, S., Allebeck, P., Engstrom, A. and Rydberg, U. (1987) Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet, 2, pp. 1483-1486.
16. Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. and Lewis, G. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ, 325, pp. 1199-1023.
17. van Os, J., Bak, M., Hassen, M., Bilj, RV, de Graaf, R. and Verdoux, H. (2002) Cannabis use and psychosis: A longitudinal population based study. Am J Epidemiol, 156, pp. 319-327.
18. Arsenault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A. and Moffitt, TE. (2002) Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ, 325, pp. 1212-1213.
19. Spear, LP. (2000) The adolescent brain and age-related behavioural manifestations. Neurosci Biobehav Rev, 24, pp. 417-463.
20. Ehrenreich, H., Rinn, T. and Kunert, HJ (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology, 142, pp. 295-301.
21. Pistis, M., Perra, S., Pillolla, G., Melis, M., Muntoni, AL and Gessa, GL. (2004) Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry, 56, pp. 86-94.
22. McGuire, P., Jones, R., Harvey, I., Williams, M., McGuffin, P. and Murray, R. (1995) Morbid risk of schizophrenia for relatives of patients with cannabis associated psychosis. Schizophr Res, 15, pp. 277-281.
23. van Os, J. and Marcelis, M. (1998) The ecogenetics of schizophrenia: A review. Schizophr Res, 32, pp. 127-135.
24. Caspi, A., Moffitt, TE and Cannon, M. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry, 15, pp. 1117-1127.
25. Meyer-Lindenberg, A. and Weinberger, DR. (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Rev. Neurosci, 7, pp. 818-827.
26. French, ED, Dillon, K. and Wu, X. (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport, 8, pp. 649-652.
27. Henquet, C., Krabbendam, L. and Spauwen, J. (2005) Prospective cohort study of cannabis use predisposition for psychosis and psychotic symptoms in young people. BMJ, 330, pp. 11-14.
28. Fergusson, DM, Horwood, LJ and Ridder, EM. (2005) Tests of causal linkages between cannabis use and psychotic symptoms. Addiction, 100, pp. 354-366.
29. Boydell, J., van Os, J. and Lambri, M. (2003) Incidence of schizophrenia in southeast London between 1965 and 1997. Br J Psychiatry, 182, pp. 45-49.
30. Boydell, J., Van Os, J. and Caspi, A. (2006) Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med, 36, pp. 1441-1446.
31. Hickman, M., Vickerman, P., Macleod, J., Kirkbride, J. and Jones, PB. (2007) Cannabis and schizophrenia: Model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction, 102, pp. 597-606.
32. Murray, RM, Morrison, PD, Henquet, C. and Di Forti, MD. (2007) Cannabis, the mind and society: The hash realities. Nat Rev Neurosci, 8, pp. 885-895.
33. Jablensky, A., McGrath, J. and Herrman, H. (2000) Psychotic disorders in urban areas: An overview of the study on low prevalence disorders. Aust N Z J Psychiatry, 34, pp. 221-236.
34. Weil, A. (1970) Adverse reactions to marihuana. N Engl J Med, 282, pp. 997-1000.
35. Bowers, MB, Mazure, CM, Nelson, JC and Jatlow, PI. (1990) Psychotogenic drug use and neuroleptic response. Schizophr Bull, 16, pp. 81-85.
36. Jablensky, A., Sartorius, N. and Ernberg, G. (1992) Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl, 20, pp. 1-97.
37. Carlsson, A. (1995) The dopamine theory revisited. Schizophrenia, pp. 379-400. Blackwell, Cambridge, MA
38. Pistis, M., Porcu, G., Melis, M., Diana, M. and Gessa, GL. (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci, 14, pp. 96-102.
39. Warner, R., Taylor, D. and Wright, J. (1994) Substance use amongst the mentally ill: Prevalence reasons for use and effects on illness. Am J Orthopsychiatry, 64, pp. 30-39.
40. Addington, J. and Duchak, V. (1997) Reasons for substance use in schizophrenia. Acta Psychiatr Scand, 96, pp. 329-333.
41. Fowler, IL, Carr, VJ, Carter, NT and Lewin, TJ. (1998) Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull, 24, pp. 443-455.
42. Peralta, V. and Cuesta, MJ. (1992) Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand, 85, pp. 127-130.
43. van der Stelt, M., Veldhuis, WB, Bar, PR, Veldink, GA, Vliegenthart, JF and Nicolay, K. (2001) Neuroprotection by 9-tetrahydrocannabinol the main active compound in marijuana against ouabain-induced in vivo excitotoxicity. J Neurosci, 21, pp. 6475-6479.
44. van der Stelt, M. and Di Marzo, V. (2005) Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat, 77, pp. 111-122.
45. Piomelli, D. (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci, 4, pp. 873-884.
46. Di Marzo, V, Melck, D., Bisogno, T. and De Petrocellis, L. (1998) Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci, 21, pp. 521-528.
47. Egertova, M., Giang, DK, Cravatt, BF and Elphick, MR. (1998) A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci, 7, pp. 2081-2085.
48. Alger, BE and Pitler, TA. (1995) Retrograde signaling at GABAA-receptor synapses in the mammalian. CNS Trends Neurosci, 18, pp. 333-340.
49. Wilson, RI and Nicoll, RA. (2002) Endocannabinoid signalling in the brain. Science, 296, pp. 678-682.
50. Auclair, N., Otani, S., Soubrie, P. and Crepel, F. (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol, 83, pp. 3287-3293.
51. Diana, MA, Levenes, C., Mackie, K. and Marty, A. (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci, 22, pp. 200-208.
52. Katona, I., Sperlagh, B. and Sik, A. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci, 19, pp. 4544-4558.
53. Tsou, K., Mackie, K., Sanudo-Pena, MC and Walker, JM. (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing gabaergic interneurons in rat hippocampal formation. Neuroscience, 93, pp. 969-975.
54. Gerdeman, GL, Partridge, J. and Lupica, CR (2003) It could be habit forming: Drugs of abuse and striatal synaptic plasticity. Trends Neurosci, 26, pp. 184-192.
55. Hoehe, MR, Caenazzo, L. and Martinez, MM (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q 14-q15. New Biol, 3, pp. 880-885.
56. Cao, Q., Martinez, M. and Zhang, JA (1997) Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics, 43, pp. 1-8.
57. Ujike, H., Takaki, M. and Nakata, K. (2002) CNR1 central cannabinoid receptor gene associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry, 7, pp. 515-518.
58. Dean, B., Sundram, S., Bradbury, R., Scarr, E. and Copolov, D. (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103, pp. 9-15.
59. Dean, B., Bradbury, R. and Copolov, DL. (2003) Cannabis-sensitive dopaminergic markers in postmortem central nervous system: Changes in schizophrenia. Biol Psychiatry, 53, pp. 585-592.
60. Zavitsanou, K., Garrick, T. and Huang, XF. (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 28, pp. 355-360.
61. Zavitsanou, K., Katsifis, A., Yu, Y. and Huang, XF. (2005) 3H]AF-DX 384 binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull, 65, pp. 397-403.
62. Leweke, FM, Giuffrida, A., Wurster, U., Emrich, HM and Piomelli, D. (1999) Elevated endogenous cannabinoids in schizophrenia. NeuroReport, 10, pp. 1665-1669.
63. Leweke, FM, Giuffrida, A. and Faulhaber, J. (2002) Endogenous cannabinoids in acute schizophrenia and other psychiatric conditions. Schizophr Res, 53, p. 226.
64. Giuffrida, A., Leweke, FM and Gerth, CW (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29, pp. 2108-2114.
65. Mackay, AVP, Iversen, LL and Rossor, M. (1982) Increased dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry, 39, pp. 991-997.
66. Okubo, Y., Suhara, T. and Suzuki, K. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385, pp. 634-636.
67. Kapur, S. (2003) Psychosis as a state of aberrant salience: A framework linking biology phenomenology and pharmacology in schizophrenia. Am J Psychiatry, 160, pp. 13-23.
68. Schultz, W. (2002) Getting formal with dopamine and reward. Neuron, 36, pp. 241-263.
69. Melis, M., Pistis, M., Perra, S., Muntoni, AL, Pillolla, G. and Gessa, GL. (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci, 7, pp. 53-62.
70. Marinelli, S. and Mercuri, NB. (2004) Cannabinoid and vanilloid receptors are activated by N-arachidonyl-dopamine in rat midbrain dopaminergic neurons. Symposium on the cannabinoids, p. 140. Burlington, Vermont
71. Melis, M., Pillollam, G. and Bisognom, T. (2006) Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis, 24, pp. 15-27.
72. Banerjee, SP, Snyder, SH and Mechoulam, R. (1975) Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther, 194, pp. 74-81.
73. Chen, J., Paredes, W., Lowinson, JH and Gardner, EI. (1990) D9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in media prefrontal cortex. Eur J Pharmacol, 190, pp. 259-262.
74. Manzoni, OJ and Bockaert, J. (2001) Cannabinoids inhibit GABAergic synaptic transmission in the mouse nucleus accumbens. Eur J Pharmacol, 412, pp. R3-R5.
75. Szabo, B., Siemes, S. and Wallmichrath, I. (2002) Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci, 15, pp. 2057-2061.
76. Tzschentke, TM. (2001) Pharmacology and behavioural pharmacology of the mesocortical dopamine system. Prog Neurobiol, 63, pp. 241-320.
77. Verrico, CD, Jentsch, JD and Roth, RH. (2003) Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated intermittent cannabinoid administration to rats. Synapse, 49, pp. 61-66.
78. Herkenham, M., Lynn, AB, Ross-Johnson, M., Melvin, LS, de Costa, BR and Rice, KC. (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci, 11, pp. 563-583.
79. Puumala, T. and Sirvio, J. (1998) Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task. Neuroscience, 83, pp. 489-499.
80. Puumala, T., Ruotsalainen, S., Jakala, P., Koivisto, E., Riekkinen Jr, P. and Sirivo, J. (1996) Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder. Neurobiol Learn Mem, 66, pp. 189-211.
81. Jentsch, JD, Andrusiak, EA, Bowers, MB and Roth, RH. (1997) Delta-9-tertahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in rats: Blockade of the dopaminergic effects by HA966. Neuropsychopharmacology, 16, pp. 426-432.
82. Knable, MB and Weinberger, DR. (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol, 11, pp. 123-131.
83. Abi-Dargham, A., Mawlawi, O. and Lombardo, I. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci, 22, pp. 3708-3719.
84. Lewis, DA, Pierri, JN, Volk, DW, Melchitzky, DS and Woo, TU. (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry, 46, pp. 616-626.
85. Spencer, KM, Nestor, PG, Niznikiewicz, MA, Salisbury, DF, Shenton, ME and McCarley, RW. (2003) Abnormal neural synchrony in schizophrenia. J Neurosci, 137, pp. 407-411.
86. Benes, FM, McSparren, J., Bird, ED, San Giovanni, JP and Vincent, SL. (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry, 48, pp. 996-1001.
87. Akbarian, S., Kim, JJ and Potkin, SG (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons of prefrontal cortex of schizophrenics. Arch Gen Psychiatry, 52, pp. 258-266.
88. Irving, AJ, Coutts, AA and Harvey, J. (2000) Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience, 98, pp. 253-262.
89. Hajos, N., Katona, I. and Naiem, SS (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci, 12, pp. 3239-3249.
90. Kim, D. and Thayer, SA. (2001) Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci, 21, p. RC146.
91. Traub, RD, Whittington, MA, Stanford, IM and Jefferys, JG. (1996) A mechanism for generation of long-range synchronous fast oscillations in the cortex. Nature, 17, pp. 621-624.
92. Moghaddam, B., Adams, B., Verma, A. and Daly, D. (1997) Activation of glutamatergic transmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci, 17, pp. 2921-2927.
93. Tsai, G., Passani, LA and Slusher, BS (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry, 528, pp. 29-36.
94. Akbarian, S., Bunney, WE and Potkin, SG (1993) Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry, 50, pp. 227-230.
95. Tamminga, CA. (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol, 12, pp. 21-36.
96. Krystal, JH, Anand, A. and Moghaddam, B. (2002) Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry, 59, pp. 663-634.
97. Sanudo-Pena, MC and Walker, JM. (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol, 77, pp. 1635-1638.
98. Takahashi, KA and Linden, DJ. (2000) Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol, 83, pp. 1167-1180.
99. Scarr, E. and Dean, B. (2001) A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin Exp Pharmacol Physiol, 28, pp. 70-73.
100. Weinberger, DR. (1999) Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry, 45, pp. 395-402.
101. Kraepelin, E. (1919) Dementia praecox and paraphrenia, Livingstone, Edinburgh
102. Weinberger, DR. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry, 44, pp. 660-669.
103. Murray, RM, O'Callaghan, E., Castle, DJ and Lewis, SW. (1992) A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull, 18, pp. 319-332.
104. Marenco, S. and Weinberger, DR. (2000) The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Dev Psychopathol, 12, pp. 501-527.
105. Fried, PA, Watkinson, B. and Gray, R. (2003) Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol, 25, pp. 427-436.
106. Huizink, AC and Mulder, EJ. (2006) Maternal smoking drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev, 30, pp. 24-41.
107. Fried, PA, Watkinson, B. and Gray, R. (1998) Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol, 20, pp. 293-306.
108. Fried, PA and Watkinson, B. (2001) Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol, 23, pp. 421-430.
109. Smith, AM, Fried, PA, Hoganc, MJ and Cameron, I. (2004) Effects of prenatal marijuana on response inhibition: An fMRI study of young adults. Neurotoxicol Teratol, 26, pp. 533-542.
110. Wang, X., Dow-Edwards, D., Keller, E. and Hurd, YL. (2003) Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience, 118, pp. 681-694.
111. Wang, X., Dow-Edwards, D., Anderson, V., Minkoff, H. and Hurd, YL. (2004) In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry, 15, pp. 909-915.
112. Panikashvili, D., Simeonidou, C. and Ben-Shabat, S. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413, pp. 527-531.
113. Berghuis, P., Dobszay, MB and Wang, X. (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA, 102, pp. 19115-19120.
114. Galve-Roperh, I., Aguado, T., Rueda, D., Velasco, G. and Guzman, M. (2006) Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des, 12, pp. 2319-2325.
115. Rueda, D., Navarro, B., Martinez-Serrano, A., Guzman, M. and Galve- Roperh, I. (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ ERK pathway. J Biol Chem, 277, pp. 46645-46650.
116. Derkinderen, P., Toutant, M. and Burgaya, F. (1996) Regulation of a neuronal form of focal adhesion kinase by anandamide. Science, 273, pp. 1719-1722.
117. Fride, E. and Mechoulam, R. (1996) Ontogenetic development of the response to anandamide and delta-9-tetrahydricannabinol in mice. Brain Res Dev Brain Res, 96, pp. 131-134.
118. Murphy, LL, Steger, RW and Bartke, A. (1990) Psychoactive and non-psychoactive cannabinoids and their effects on reproductive neuroendocrine parameters. Biochemistry and physiology of substance abuse, 2, pp. 73-94. CRC Press, Boca Raton, FL
119. Vela, G., Fuentes, JA, Bonnin, A., Fernandez-Ruiz, JJ and Ruiz-Gayo, M. (1995) Perinatal exposure to D9-tetrahydrocannabinol (D9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Res, 680, pp. 142-147.
120. Fride, E. and Weinstock, M. (1988) Prenantal stress increases anxiety related behaviour and alters cerebral lateralization of dopamine activity. Life Sci, 42, pp. 1059-1065.
121. Bonnin, A., de Miguel, R., Castro, JG, Ramos, JA and Fernandez-Ruiz, JJ. (1996) Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J Mol Neurosci, 7, pp. 291-308.
122. Navarro, M., Rodriguez de Fonseca, F, Hernandez, ML, Ramos, JA and Fernandez-Ruiz, JJ. (1994) Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Pharmacol Biochem Behav, 47, pp. 47-58.
123. Navarro, M., de Miguel, R., Rodríguez de Fonseca, Ramos, FJA and Fernandez-Ruiz, JJ (1996) Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Behav Brain Res, 75, pp. 91-98.
124. Mokler, DA, Robinson, SE, Johnson, JH, Hong, JS and Rosecrans, JA. (1987) Neonatal administration of D9-tetrahydrocannabinol alters the neurochemical response to stress in the adult Fischer-344 rat. Neurotoxicol Teratol, 9, pp. 321-326.
125. Vela, G., Martin, S. and Garcia-Gil, L. (1998) Maternal exposure to D9-tetrahydrocannabinol facilitates morphine self-administration and changes A opioid receptor binding in brain regions related to drug reinforcement in adult offspring female rats. Brain Res, 807, pp. 101-109.
126. Navarro, M., Rubio, P. and Rodriguez de Fonseca, F. (1995) Behavioral consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology, 122, pp. 1-14.
127. Schneider, M. and Koch, M. (2003) Chronic pubertal but not adult chronic cannabinoid treatment impairs sensorimotor gating recognition memory and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology, 28, pp. 1760-1769.
128. Moore, THM, Zammit, S. and Lingford-Hughes, A. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, pp. 319-328.